PF-07820435
- Generic Name
- PF-07820435
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- MelanomaUrothelial CarcinomaColorectal CarcinomaNeoplasmsNon-small-cell Lung CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell CarcinomaOvarian Carcinoma
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT06285097
- Locations
- 🇺🇸
Florida Cancer Specialists Sarasota Drug Development Unit, Sarasota, Florida, United States
🇺🇸Corewell Health (reference non-engagement letter), Grand Rapids, Michigan, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath